Has shown unprecedented activity against M. hyopneumoniae in vitro and in vivo also
showed exceptional efficacy. In two artificial challenge studies (Morgan et al, 1996)
using lung homogenate containing M. hyopneumoniae, valnemulin was given for 21 days
in feed at a variety of inclusion rates following infection with two isolates with different
MICs.